rozrolimupab recombinant antibody mixture specifically containing rhesus rhd human antibodies currently development symphogen treatment immune thrombocytopenic purpura itp prevention hemolytic disease newborn phase two trials proved promising utilizing single intravenous infusion dosing phase held centers across united states europe asia order evaluate effective patient study assessing rozrolimupabs ability effectively treat itp hdn well safe tolerable drug common adverse effects included mild moderate headache pyrexia chills fatique study showed administration drug effect platelet responses blood median time response roughly two half days average lasting total current bloodderived treatment proved successful dependence donor population proves problematic rozrolimupabs manufactured antibody mixture may drug article relating blood blood forming organs stub help wikipedia expanding httpsenwikipediaorgwikirozrolimupab